Suchergebnisse - "Clinical Trial, Phase III"

PubPharm (8)

1

Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothelial carcinoma after surgical resection (IMvigor010)- study AB 53/15 of the AUO

enthalten in: Der Urologe. Ausg. A | 2016

von Rexer, H. | Retz, M. | Albers, P.

2

First-line treatment for advanced renal cell carcinoma : A phase 3, open-label, randomized study of Atezolizumab (Anti-PD-L1-Antibody) in combination with Bevacizumab versus Sunitinib in patients with untreated advanced renal cell carcinoma ("IMmotion") - AN 37/15 der AUO

enthalten in: Der Urologe. Ausg. A | 2016

von Rexer, H. | Doehn, C.

3

First-line treatment of unresectable, stage IV transitional cell carcinoma

enthalten in: Der Urologe. Ausg. A | 2016

von Rexer, H. | Ohlmann, C.

4

Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition

enthalten in: Der Urologe. Ausg. A | 2016

von Oppel-Heuchel, H. | Grimm, M.

5

Severe atopic dermatitis. Antibodies revolutionize therapy

enthalten in: MMW Fortschritte der Medizin | 2015

6

Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36/15 of the AUO)

enthalten in: Der Urologe. Ausg. A | 2015

von Rexer, H.

7

In Process Citation

enthalten in: Aktuelle Urologie | 2015

8

New approaches in LDL cholesterol reduction

enthalten in: MMW Fortschritte der Medizin | 2015

von Füeßl, H.

1
[1]